|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF114 |
Gene summary for ZNF114 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF114 | Gene ID | 163071 |
| Gene name | zinc finger protein 114 | |
| Gene Alias | ZNF114 | |
| Cytomap | 19q13.33 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8NC26 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 163071 | ZNF114 | HCC1 | Human | Liver | HCC | 8.72e-04 | 6.47e-01 | 0.5336 |
| 163071 | ZNF114 | HCC2 | Human | Liver | HCC | 8.70e-17 | 1.18e+00 | 0.5341 |
| 163071 | ZNF114 | HCC5 | Human | Liver | HCC | 5.72e-20 | 1.11e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF114 | SNV | Missense_Mutation | rs762508022 | c.100N>A | p.Val34Met | p.V34M | Q8NC26 | protein_coding | deleterious(0) | possibly_damaging(0.894) | TCGA-A2-A0YE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Taxotere | SD |
| ZNF114 | SNV | Missense_Mutation | c.430N>C | p.Asp144His | p.D144H | Q8NC26 | protein_coding | tolerated(0.06) | possibly_damaging(0.718) | TCGA-D8-A1JN-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozolum | SD | |
| ZNF114 | SNV | Missense_Mutation | novel | c.1225N>G | p.Thr409Ala | p.T409A | Q8NC26 | protein_coding | tolerated(0.2) | benign(0.003) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF114 | insertion | Frame_Shift_Ins | novel | c.1062_1063insCT | p.Val355LeufsTer26 | p.V355Lfs*26 | Q8NC26 | protein_coding | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNF114 | insertion | Frame_Shift_Ins | novel | c.1063_1064insAGAAAGATGAATCTCCTGTTAGCAT | p.Val355GlufsTer18 | p.V355Efs*18 | Q8NC26 | protein_coding | TCGA-A8-A093-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNF114 | SNV | Missense_Mutation | c.773N>A | p.Arg258Lys | p.R258K | Q8NC26 | protein_coding | tolerated(0.93) | benign(0.021) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZNF114 | SNV | Missense_Mutation | c.1090N>A | p.Glu364Lys | p.E364K | Q8NC26 | protein_coding | tolerated(1) | benign(0.007) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ZNF114 | SNV | Missense_Mutation | novel | c.5C>T | p.Ser2Phe | p.S2F | Q8NC26 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.965) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ZNF114 | SNV | Missense_Mutation | c.508A>G | p.Thr170Ala | p.T170A | Q8NC26 | protein_coding | deleterious(0.05) | benign(0.063) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| ZNF114 | SNV | Missense_Mutation | novel | c.615N>G | p.Asn205Lys | p.N205K | Q8NC26 | protein_coding | tolerated(0.2) | benign(0.338) | TCGA-AA-A01C-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |